AnaptysBio Unleashes Dual Powerhouse: Splitting into Dedicated Immunology and Oncology Ventures

In a bold strategic move designed to unleash specialized focus and unlock enhanced shareholder value, AnaptysBio (NASDAQ:ANAB) has announced its intention to split its operations into two distinct, publicly traded companies. This significant restructuring will create one entity entirely dedicated to advancing immunology therapies and another solely focused on groundbreaking oncology treatments.

The current AnaptysBio will transform into a pure-play immunology company, retaining its robust pipeline of innovative treatments.

Its crown jewel remains imsidolimab, a promising therapy targeting Generalized Pustular Psoriasis (GPP), for which it awaits potential regulatory approval. Beyond GPP, imsidolimab is also in development for eosinophilic asthma and hidradenitis suppurativa (HS), addressing critical unmet needs in these inflammatory conditions.

This focused immunology entity is projected to maintain a strong financial position, with a cash runway extending well into the first quarter of 2026, ensuring sustained development efforts.

Concurrently, a new, yet-to-be-named oncology company will emerge, becoming a dedicated force in the fight against cancer.

This innovative spin-off will concentrate its efforts on two highly promising assets: ANB032, an anti-PD-1 agonist, and ANB030, an anti-BTLA agonist. These novel immunotherapies represent cutting-edge approaches to cancer treatment, aiming to modulate the body's immune response to target malignant cells more effectively.

Similar to its immunology counterpart, the new oncology venture is also expected to boast a healthy cash runway, projected through the first quarter of 2026, providing the necessary resources for its ambitious development programs.

The company anticipates that this transformative separation will be executed through a tax-free distribution to AnaptysBio's current shareholders.

This structure is designed to provide existing investors with shares in both the immunology and oncology companies, effectively creating two distinct and attractive investment opportunities. The leadership team is targeting the completion of this strategic split by the end of the first quarter of 2025, marking a pivotal moment in AnaptysBio's evolution.

Accompanying this organizational shift will be a change in executive leadership.

Daniel Francis, currently AnaptysBio's Chief Financial Officer, will step into the role of Chief Executive Officer for the newly focused immunology company. Marco Londei, the current Chief Operating Officer, will assume the CEO position for the nascent oncology company. This transition also marks the retirement of current CEO Paul L.

Hastings, who has guided AnaptysBio through significant growth phases. This carefully considered leadership structure is set to provide each new entity with dedicated expertise and vision, ensuring their respective pipelines are advanced with precision and urgency.

This strategic bifurcation is poised to unlock significant value by allowing each company to sharpen its focus, optimize resource allocation, and attract specialized investor interest.

By creating two distinct enterprises, AnaptysBio is not just splitting its assets; it's doubling down on innovation, aiming to accelerate the delivery of vital new therapies to patients in both the immunology and oncology spheres.